宜明昂科-B:IMM0306获国家药监局批准进行狼疮性肾炎治疗的II期临床试验

格隆汇资讯
02 Dec 2024

格隆汇12月2日丨宜明昂科-B(01541.HK)发布公告,集团已获中国国家药品监督管理局(“国家药监局”)批准进行IMM0306(一种靶向CD47xCD20的原创新药双特异性抗体)用于治疗狼疮性肾炎(LN)的II期临床试验。由集团独立研发的IMM0306是一种靶向分化簇47(CD47)及分化簇20(CD20)的双特异性分子,是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10